Published :
Tables : 52
Figures : 42
Category : Healthcare
No. of Pages : 250
Report Code : HC-U2040
Patient Derived Xenograft Models Market is forecasted to value over USD 240 million by 2027 end and register a CAGR of 15% from the forecast period 2020-2027. FutureWise Market Research has illustrated a report on the Patient Derived Xenograft Models Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market. The Patient Derived Xenograft Models market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Patient Derived Xenograft Models market are: • Crown Bioscience Inc. (US) • WuXi AppTec (China) • Champions Oncology, Inc. (US) • The Jackson Laboratory (US) • ONCODESIGN (France) • Charles River Laboratories International, Inc. (US) • EPO Berlin-Buch GmBH (Germany) • Shanghai LIDE Biotech Co., Ltd (China) • Xentech (France) • Horizon Discovery Group PLC (UK) (Note: The list of the major players will be updated with the latest market scenario and trends) Patient Derived Xenograft Models Market Segmentation: By Type Mice Models Rat Models By Tumor Type Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors) Gynecological Tumor Models (breast, ovarian, and cervical tumors) Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors) Urological Tumor Models (renal, prostate, and bladder tumors) Hematological Tumor Models (leukemia and lymphoma) Other Tumor Models (head & neck cancer, sarcoma, and melanoma) By Application Pre-clinical Drug Development and Basic Cancer Research Biomarker Analysis By End User Pharmaceutical & Biotechnology Companies Contract Research Organizations Academic & Research Institutions By Region • North America • Europe • Asia-Pacific • Rest of the world Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the market by type, by tumor type, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key countries— China, Japan, Korea, India, Singapore, Indonesia, Australia and rest of Asia • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
FutureWise Market Research has illustrated a report on the Patient Derived Xenograft Models Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.
The Patient Derived Xenograft Models market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical. Major players included in the Patient Derived Xenograft Models market are: • Crown Bioscience Inc. (US) • WuXi AppTec (China) • Champions Oncology, Inc. (US) • The Jackson Laboratory (US) • ONCODESIGN (France) • Charles River Laboratories International, Inc. (US) • EPO Berlin-Buch GmBH (Germany) • Shanghai LIDE Biotech Co., Ltd (China) • Xentech (France) • Horizon Discovery Group PLC (UK) (Note: The list of the major players will be updated with the latest market scenario and trends)
Patient Derived Xenograft Models Market Segmentation:
By Type
By Tumor Type
By Application
By End User
By Region • North America • Europe • Asia-Pacific • Rest of the world Competitive Landscape: • Tier 1 players- established companies in the market with a major market share • Tier 2 players • Emerging players which are growing rapidly • New Entrants FutureWise Key Takeaways: • Growth prospects • SWOT analysis • Key trends • Key data-points affecting market growth Objectives of the Study: • To provide with an exhaustive analysis on the market by type, by tumor type, by application, by end user and by region • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) • To evaluate and forecast micro-markets and the overall market • To predict the market size, in key countries— China, Japan, Korea, India, Singapore, Indonesia, Australia and rest of Asia • To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Flexible Delivery Model: • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement • The customization services offered are free of charge with purchase of any license of the report. • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. Global Patient Derived Xenograft Models Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Global Patient Derived Xenograft Models Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Patient Derived Xenograft Models Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. Global Patient Derived Xenograft Models Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. Global Patient Derived Xenograft Models Market, By Tumor Type Historical Analysis and Forecast 2020-2027 (USD Million) 7.1 Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors) 7.2 Gynecological Tumor Models (breast, ovarian, and cervical tumors) 7.3 Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors) 7.4 Urological Tumor Models (renal, prostate, and bladder tumors) 7.5 Hematological Tumor Models (leukemia and lymphoma) 7.6 Other Tumor Models (head & neck cancer, sarcoma, and melanoma) 8. Global Patient Derived Xenograft Models Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million) 8.1. Mice Models 8.2. Rat Models 9. Global Patient Derived Xenograft Models Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million) 9.1. Pre-clinical Drug Development and Basic Cancer Research 9.2. Biomarker Analysis 10. Global Patient Derived Xenograft Models Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million) 10.1. Pharmaceutical & Biotechnology Companies 10.2. Contract Research Organizations 10.3. Academic & Research Institutions 11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2020-2027 12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2020-2027 13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2020-2027 14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027 15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019 15.2.1. Saudi Arabia 15.2.2. UAE 15.2.3. South Africa 15.2.4. Egypt 15.3. Market Size (USD Million) Forecast for MEA 2020-2027 16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts) 16.1 Crown Bioscience Inc. (US) 16.1.1. Company Overview (HQ, Business Segments, Employee Strength) 16.1.2. Product Portfolio 16.1.3. SWOT Analysis 16.1.4. Financial Overview 16.1.5. Strategic Overview 16.2 WuXi AppTec (China) 16.2.1. Company Overview (HQ, Business Segments, Employee Strength) 16.2.2. Product Portfolio 16.2.3. SWOT Analysis 16.2.4. Financial Overview 16.2.5. Strategic Overview 16.3 Champions Oncology, Inc. (US) 16.3.1. Company Overview (HQ, Business Segments, Employee Strength) 16.3.2. Product Portfolio 16.3.3. SWOT Analysis 16.3.4. Financial Overview 16.3.5. Strategic Overview 16.4 The Jackson Laboratory (US) 16.4.1. Company Overview (HQ, Business Segments, Employee Strength) 16.4.2. Product Portfolio 16.4.3. SWOT Analysis 16.4.4. Financial Overview 16.4.5. Strategic Overview 16.5 ONCODESIGN (France) 16.5.1. Company Overview (HQ, Business Segments, Employee Strength) 16.5.2. Product Portfolio 16.5.3. SWOT Analysis 16.5.4. Financial Overview 16.5.5. Strategic Overview 16.6 Charles River Laboratories International, Inc. (US) 16.6.1. Company Overview (HQ, Business Segments, Employee Strength) 16.6.2. Product Portfolio 16.6.3. SWOT Analysis 16.6.4. Financial Overview 16.6.5. Strategic Overview 16.7 EPO Berlin-Buch GmBH (Germany) 16.7.1. Company Overview (HQ, Business Segments, Employee Strength) 16.7.2. Product Portfolio 16.7.3. SWOT Analysis 16.7.4. Financial Overview 16.7.5. Strategic Overview 16.8 Shanghai LIDE Biotech Co., Ltd (China) 16.8.1. Company Overview (HQ, Business Segments, Employee Strength) 16.8.2. Product Portfolio 16.8.3. SWOT Analysis 16.8.4. Financial Overview 16.8.5. Strategic Overview 16.9 Xentech (France) 16.9.1. Company Overview (HQ, Business Segments, Employee Strength) 16.9.2. Product Portfolio 16.9.3. SWOT Analysis 16.9.4. Financial Overview 16.9.5. Strategic Overview 16.10 Horizon Discovery Group PLC (UK) 16.10.1. Company Overview (HQ, Business Segments, Employee Strength) 16.10.2. Product Portfolio 16.10.3. SWOT Analysis 16.10.4. Financial Overview 16.10.5. Strategic Overview 17. FutureWise SME Key Takeaway Points for Client
1. Market Introduction
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Scope
1.3.1. Years Considered for the Study
1.3.2. Market Covered
1.4. Currency
1.5. Limitations
1.6. Stakeholders
2. Research Methodology
2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data
2.1.2.1. Key Data from Primary Sources
2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation
2.4. Assumptions for the Study
3. Executive Summary
3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. Global Patient Derived Xenograft Models Market Variables, Trends & Scope
4.1. Market Lineage Outlook
4.2. Penetration and Growth Prospect Mapping
4.3. Industry Value Chain Analysis
4.4. Cost Analysis Breakdown
4.5. Technology Overview
4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Global Patient Derived Xenograft Models Market Overview
5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of Patient Derived Xenograft Models Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. Global Patient Derived Xenograft Models Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. Global Patient Derived Xenograft Models Market, By Tumor Type Historical Analysis and Forecast 2020-2027 (USD Million)
7.1 Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
7.2 Gynecological Tumor Models (breast, ovarian, and cervical tumors)
7.3 Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
7.4 Urological Tumor Models (renal, prostate, and bladder tumors)
7.5 Hematological Tumor Models (leukemia and lymphoma)
7.6 Other Tumor Models (head & neck cancer, sarcoma, and melanoma) 8. Global Patient Derived Xenograft Models Market, By Type Historical Analysis and Forecast 2020-2027 (USD Million)
8.1. Mice Models
8.2. Rat Models
9. Global Patient Derived Xenograft Models Market, By Application Historical Analysis and Forecast 2020-2027 (USD Million)
9.1. Pre-clinical Drug Development and Basic Cancer Research
9.2. Biomarker Analysis
10. Global Patient Derived Xenograft Models Market, By End User Historical Analysis and Forecast 2020-2027 (USD Million)
10.1. Pharmaceutical & Biotechnology Companies
10.2. Contract Research Organizations
10.3. Academic & Research Institutions
11. North America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
11.1. Introduction
11.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
11.2.1. U.S.A
11.2.2. Canada
11.2.3. Mexico
11.3. Market Size (USD Million) Forecast for North America 2020-2027
12. Latin America Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
12.1. Introduction
12.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
12.2.1. Brazil
12.2.2. Venezuela
12.2.3. Argentina
12.2.4. Rest of Latin America
12.3. Market Size (USD Million) Forecast for Latin America 2020-2027
13. Europe Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
13.1. Introduction
13.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
13.2.1. Germany
13.2.2. U.K
13.2.3. France
13.2.4. Italy
13.2.5. Spain
13.2.6. Russia
13.2.7. Poland
13.2.8. Rest of Europe
13.3. Market Size (USD Million) Forecast for Europe 2020-2027
14. Asia Pacific Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
14.1. Introduction
14.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
14.2.1. Japan
14.2.2. China
14.2.3. India
14.2.4. Australia and New Zealand
14.2.5. ASEAN
14.2.6. Rest of Asia Pacific
14.3. Market Size (USD Million) Forecast for Asia Pacific 2020-2027
15. Middle East and Africa Market Analysis 2015–2019 and Forecast 2020–2027 (USD Million)
15.1. Introduction
15.2. Historical Market Size (USD Million) Analysis By Country, 2015-2019
15.2.1. Saudi Arabia
15.2.2. UAE
15.2.3. South Africa
15.2.4. Egypt
15.3. Market Size (USD Million) Forecast for MEA 2020-2027
16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
16.1 Crown Bioscience Inc. (US)
16.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.1.2. Product Portfolio
16.1.3. SWOT Analysis
16.1.4. Financial Overview
16.1.5. Strategic Overview
16.2 WuXi AppTec (China)
16.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.2.2. Product Portfolio
16.2.3. SWOT Analysis
16.2.4. Financial Overview
16.2.5. Strategic Overview
16.3 Champions Oncology, Inc. (US)
16.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2. Product Portfolio
16.3.3. SWOT Analysis
16.3.4. Financial Overview
16.3.5. Strategic Overview
16.4 The Jackson Laboratory (US)
16.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.4.2. Product Portfolio
16.4.3. SWOT Analysis
16.4.4. Financial Overview
16.4.5. Strategic Overview
16.5 ONCODESIGN (France)
16.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.5.2. Product Portfolio
16.5.3. SWOT Analysis
16.5.4. Financial Overview
16.5.5. Strategic Overview
16.6 Charles River Laboratories International, Inc. (US)
16.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.6.2. Product Portfolio
16.6.3. SWOT Analysis
16.6.4. Financial Overview
16.6.5. Strategic Overview
16.7 EPO Berlin-Buch GmBH (Germany)
16.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.7.2. Product Portfolio
16.7.3. SWOT Analysis
16.7.4. Financial Overview
16.7.5. Strategic Overview 16.8 Shanghai LIDE Biotech Co., Ltd (China)
16.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.8.2. Product Portfolio
16.8.3. SWOT Analysis
16.8.4. Financial Overview
16.8.5. Strategic Overview
16.9 Xentech (France)
16.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.9.2. Product Portfolio
16.9.3. SWOT Analysis
16.9.4. Financial Overview
16.9.5. Strategic Overview
16.10 Horizon Discovery Group PLC (UK)
16.10.1. Company Overview (HQ, Business Segments, Employee Strength)
16.10.2. Product Portfolio
16.10.3. SWOT Analysis
16.10.4. Financial Overview
16.10.5. Strategic Overview
17. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics